-
2025-520565-51-00
5
2026-06-23
small cell lung cancer
-
2025-522983-33-00
5
2026-06-23
Chronic rhinosinusitis with nasal polyps
-
2025-523576-23-00
5
2026-06-12
Unresectable Stage III non-small cell lung cancer without progression
-
2025-523586-18-00
5
2026-06-11
Non-Small Cell Lung Cancer
-
2025-521590-13-00
5
2026-05-28
Moderately to Severely Active Crohn’s Disease
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2023-508047-40-00
5
2026-04-30
Ovarian cancer
-
2024-519830-22-00
5
2026-04-27
Heart failure due to systemic left ventricular systolic dysfunction
-
2024-517943-29-00
5
2026-04-21
Pulmonary Hypertension associated with interstitial lung disease (WHO
-
2024-519359-27-00
4
2026-04-16
Acute radiation proctitis symptoms in male patients aged 18 years or o
-
2025-521792-31-01
5
2026-04-07
Homozygous Familial Hypercholesterolemia (HoFH)
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2023-503293-21-00
5
2026-03-25
Osteogenesis Imperfecta
-
2025-520805-10-00
5
2026-03-12
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2025-521558-40-00
5
2026-02-12
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2024-520097-36-00
5
2026-01-07
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2025-521268-37-00
6
2025-11-25
Respiratory tract diseases
-
2025-521511-40-00
10
2025-11-18
metastatic non-small cell lung cancer
-
2023-507192-22-00
7
2025-10-24
Methyl CpG binding protein 2 (MECP2) Duplication Syndrome (MDS)
-
2023-508057-19-00
5
2025-09-23
Advanced HER2-expressing Biliary Tract Cancer
-
2024-517968-36-00
5
2025-07-08
non-small cell lung cancer